pharmaceutical investing Pfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026
pharmaceutical investing Pfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer
pharmaceutical investing Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026
pharmaceutical investing Pfizer's LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo
pharmaceutical investing Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
pharmaceutical investing Pfizer Advances Today's Cancer Care and Tomorrow's Potential Breakthroughs at ESMO
pharmaceutical investing Pfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with Analysts
pharmaceutical investing Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine
pharmaceutical investing Pfizer and Valneva's Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
pharmaceutical investing Pfizer Reports Second-Quarter Results And Raises Midpoint of 2026 Revenue Guidance
pharmaceutical investing Pfizer Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo
pharmaceutical investing European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union
pharmaceutical investing FDA Grants Priority Review for Pfizer's TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
pharmaceutical investing U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
BriaCell Announces ESMO 2026 Poster Highlighting Circulating Immune Biomarker Associated with Clinical Outcomes in Metastatic Breast Cancer
